Please assess the completion status of the following clinical trial:

Trial Title: Effect of Liraglutide on the Beta-cell Responsiveness in Subjects With Type 2 Diabetes Compared to a Healthy Control Group

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with type 2 diabetes, either newly diagnosed with at least 2 months of diet or on OAD monotherapy for at least 3 months~* Body Mass Index (BMI): 24-35 kg/m\^2 inclusive~Exclusion Criteria:~* SUBJECTS WITH TYPE 2 DIABETES~* Receipt of any investigational drug within three months prior to this trial~* Recurrent severe hypoglycemia as judged by the investigator~* Cardiac disease~* Use of any drug (except an OAD (oral anti-diabetic drug)) that in the investigator's opinion could interfere with the blood glucose level~* Haemoglobin maximum 10 g/L~* HbA1c above 12%~* Loss of more than 400 mL blood during the 3 months prior to trial start~* HEALTHY SUBJECTS~* Receipt of any investigational drug within 3 months prior to this trial~* Clinically relevant cardiac disease or any clinically significant abnormal ECG (electrocardiogram)~* Use of any drug that in the investigator's opinion could interfere with the blood glucose level~* Haemoglobin max. 10 g/L~* HbA1c at least 6%

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- NNC 90-1170 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None
- Healthy (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).